Clinical Trials Arena on MSN
Strategies to optimise patient engagement and retention in clinical trials
At OCTSC, an expert delved into how to optimise patient enrollment to achieve retention and clinical trial success.
James is a pulmonary and critical care physician specializing in sarcoidosis. When one of my patients was first diagnosed with sarcoidosis, her specialist gave her two options: take steroids or join a ...
Patient burden should join standard operational metrics like cost, timelines, and regulatory compliance to ensure long-term clinical trial success, argues Christine Von Raesfeld, patient advocate with ...
In psoriasis, like cancers, disease control that includes the well-being of a patient is an additional useful measure of ...
Avik Pal, Founder and CEO of CliniOps, a technology and data company with multiple patents to digitize global clinical trials. When Michael J. Fox and Stephen Hawking publicly shared their personal ...
With the future of her cancer treatment in limbo, Natalie Phelps doesn’t know how much longer she can wait. Last month, after months of seeking treatment options for her colorectal cancer, the 43-year ...
GlobalData on MSN
Europe’s path to maintaining clinical trial hotbed of innovation
The Annual Outsourcing in Clinical Trials & Clinical Trial Supply Nordics 2025 conference will gather experts to discuss ...
"The idea is that any provider all over the world potentially participates in a clinical trial," Oracle' Seema Verma said.
The U.S. Food and Drug Administration recently approved Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) for ...
Many people think of clinical trials as a last-ditch effort for cancer patients. In 2025, amid a flurry of new treatments enabling people diagnosed with cancer to live longer and better, ...
This innovative tech collaboration addresses emotional, logistical and financial challenges associated with international clinical trial recruitment, accelerating access to groundbreaking treatments ...
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results